Traws Pharma
TRAW
24 hedge funds and large institutions have $1.04M invested in Traws Pharma in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 7 reducing their positions, and 6 closing their positions.
3% more capital invested
Capital invested by funds: $1.01M → $1.04M (+$32.4K)
0.03% less ownership
Funds ownership: 0.3% → 0.27% (-0.03%)
14% less funds holding
Funds holding: 28 → 24 (-4)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
86% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$24.6K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$4.54K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
+$865 |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$108 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BPA
Beacon Pointe Advisors
Newport Beach,
California
|
-$22.7K |
| 2 |
Two Sigma Advisers
New York
|
-$20.3K |
| 3 |
Millennium Management
New York
|
-$20K |
| 4 |
Renaissance Technologies
New York
|
-$19.8K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$12K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
26
Virtu Financial
New York
| – | -$11K | -679 | Closed |
|
|
SG
27
StoneX Group
New York
| – | -$8.44K | -523 | Closed |
|
28
Simplex Trading
Chicago,
Illinois
| – | -$2.71K | -125 | Closed |
|
|
GWS
29
Glassman Wealth Services
Vienna,
Virginia
| – | -$86 | -5 | Closed |
|
TRAW Hedge Fund Activity: Q1 2023 in Review
24 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q1 2023, worth a combined $1.04M — up 3.2% from $1.01M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of TRAW and 3 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 1 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $24.6K. The largest seller was Beacon Pointe Advisors, cutting an estimated $22.7K.
- 24 institutional investors held Traws Pharma (TRAW) as of Q1 2023, down from 28 in Q4 2022.
- Funds reported $1.04M of Traws Pharma stock for Q1 2023, up 3.2% quarter-over-quarter.
- 3 funds opened new Traws Pharma positions in Q1 2023 and 6 closed out, a net change of -3 holders.
- The largest Traws Pharma buyer in Q1 2023 was Susquehanna International Group, an estimated $24.6K added.
- The largest Traws Pharma seller in Q1 2023 was Beacon Pointe Advisors, an estimated $22.7K sold.
Based on aggregated 13F filings for Q1 2023.